



ERRATA

Errata in “Potential adverse effects of thyrotropin-suppressive therapy in differentiated thyroid carcinoma”

Jordi L. Reverter,* Eulalia Colomé

Servei d'Endocrinologia i Nutrició, Departament de Medicina, Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain

An error was detected in Table 2 (page 79) of the article “Potential adverse effects of thyrotropin-suppressive therapy in differentiated thyroid carcinoma” (Endocrinol Nutr. 2011;58(2):75-83). The correct table is given below:

Table 2 Proposed stratification of TSH goals based on the risk of relapse or progression of thyroid cancer and the risk of eventual complications of subclinical thyrotoxicosis due to TSH inhibitory therapy.

	Risk from differentiated thyroid cancer	
	High	Low
<i>Potential risk of TSH suppression</i>		
High	TSH 0.1-0.5 mU/L	TSH 0.5-2 mU/L
Low	TSH < 0.1 mU/L (undetectable?)	TSH 0.5-2 mU/L

Taken from reference 105.

*Corresponding author.

E-mail address: reverter.germanstrias@gencat.cat (J.L. Reverter).